Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma

  • Technology appraisal guidance
  • TA462
  • Published: 
Download guidance (PDF)

1 Recommendations

1.1 Nivolumab is recommended, within its marketing authorisation, as an option for treating relapsed or refractory classical Hodgkin lymphoma in adults after autologous stem cell transplant and treatment with brentuximab vedotin, when the company provides nivolumab according to the commercial arrangement.